Skip to main content

Advertisement

SpringerLink
Log in

Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Platinum-resistant ovarian cancer (PROC) is usually treated with single-agent chemotherapy. A synergistic effect of gemcitabine and platinum has been reported in PROC. We evaluated the efficacy and safety of gemcitabine and carboplatin with or without bevacizumab (GC ± B) in patients with PROC.

Methods

From April 2014 to April 2018, patients with PROC received gemcitabine on days 1 and 8, and carboplatin on day 1, with or without bevacizumab (Bev) on day 1 every 3 weeks. The primary endpoint was objective response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and rate of adverse events.

Results

In total, 215 cycles were administered to 31 patients, of whom 21 received Bev and the median number of cycle for each patient was 6 (range, 2–19). The median platinum-free interval (PFI) was 4 months. The ORR and DCR were 51.9% and 92.6%, respectively. Median PFS and OS were 7.9 months and 16.1 months, respectively. PFS and OS of patients with 3–6 months PFI were significantly longer than those with PFI < 3 months (median PFS, 9.7 vs. 5.8 months; p < 0.01; median OS, 20.0 vs. 12.1 months; p = 0.03). Grade 3 or 4 hematological toxicities observed included neutropenia (71.0%), leukopenia (54.8%), anemia (51.6%), and thrombocytopenia (25.8%). No other grade 2–4 nonhematological toxicity was observed except for hypertension in one and CBDCA hypersensitivity reaction in two.

Conclusion

GC ± B may be effective and safe treatment alternative for PROC, especially with PFI of 3–6 months, despite hematological toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

    Article  Google Scholar 

  2. National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html

  3. Vital Statistics in Japan, tabulated by Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html

  4. Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384:1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7

    Article  PubMed  Google Scholar 

  5. Pignata S, Cecere SC, Du Bois A et al (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28:viii51–viii56. https://doi.org/10.1093/annonc/mdx441

    Article  CAS  PubMed  Google Scholar 

  6. Ushijima K (2010) Treatment for recurrent ovarian cancer—at first relapse. J Oncol. https://doi.org/10.1155/2010/497429

    Article  PubMed  Google Scholar 

  7. Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811–2818. https://doi.org/10.1200/JCO.2006.09.6735

    Article  CAS  PubMed  Google Scholar 

  8. Gordon AN, Tonda M, Sun S et al (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8. https://doi.org/10.1016/j.ygyno.2004.07.011

    Article  CAS  PubMed  Google Scholar 

  9. ten Bokkel HW, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100–103. https://doi.org/10.1093/annonc/mdh025

    Article  Google Scholar 

  10. Rose PG, Blessing JA, Mayer AR et al (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 16:405–410. https://doi.org/10.1200/JCO.1998.16.2.405

    Article  CAS  PubMed  Google Scholar 

  11. Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308. https://doi.org/10.1200/JCO.2013.51.4489

    Article  CAS  PubMed  Google Scholar 

  12. Flchtlnger-Schepman AMJ, Van Dijk-knijnenburg HCM, Van Der Velde-visser SD et al (1995) Cisplatin- and carboplatin-DNA adducts: is pt-ag the cytotoxic lesion? Carcinogenesis 16:2447–2453. https://doi.org/10.1093/carcin/16.10.2447

    Article  Google Scholar 

  13. McHugh PJ, Spanswick VJ, Hartley JA (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2:483–490. https://doi.org/10.1016/S1470-2045(01)00454-5

    Article  CAS  PubMed  Google Scholar 

  14. Wynne P, Newton C, Ledermann JA et al (2007) Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 97:927–933. https://doi.org/10.1038/sj.bjc.6603973

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. D’Agostino G, Amant F, Berteloot P et al (2003) Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88:266–269. https://doi.org/10.1016/S0090-8258(03)00011-8

    Article  CAS  PubMed  Google Scholar 

  16. Ledermann JA, Gabra H, Jayson GC et al (2010) Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res 16:4899–4905. https://doi.org/10.1158/1078-0432.CCR-10-0832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hansen MKG, Smerdel MP, Waldstrøm M et al (2020) Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. Cancer Chemother Pharmacol 86:751–759. https://doi.org/10.1007/s00280-020-04162-5

    Article  CAS  PubMed  Google Scholar 

  18. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  19. John G, Rustin S, Vergote I et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer 21:419–423. https://doi.org/10.1097/IGC.0b013e3182070f17

    Article  Google Scholar 

  20. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756. https://doi.org/10.1200/JCO.1989.7.11.1748

    Article  CAS  PubMed  Google Scholar 

  21. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580

    Article  CAS  PubMed  Google Scholar 

  22. Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045. https://doi.org/10.1200/JCO.2012.42.0505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Greenwood M (1926) The natural duration of cancer. Reports on Public Health and Medical Subjects. London: Her Majesty's Stationery Office. 33:1–26

  24. Ferrandina G, Ludovisi M, Lorusso D et al (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890–896. https://doi.org/10.1200/JCO.2007.13.6606

    Article  CAS  PubMed  Google Scholar 

  25. Brewer CA, Blessing JA, Nagourney RA et al (2006) Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103:446–450. https://doi.org/10.1016/j.ygyno.2006.03.018

    Article  CAS  PubMed  Google Scholar 

  26. Sharma R, Graham J, Mitchell H et al (2009) Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 100:707–712. https://doi.org/10.1038/sj.bjc.6604914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lortholary A, Largillier R, Weber B et al (2012) Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from groupe d’investigateurs nationaux pour l’etude des cancers ovariens (GINECO). Ann Oncol 23:346–352. https://doi.org/10.1093/annonc/mdr149

    Article  CAS  PubMed  Google Scholar 

  28. Oncologico I, Buda A, Floriani I et al (2004) Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the “Mario Negri” Institut. Br J Cancer 90:2112–2117. https://doi.org/10.1038/sj.bjc.6601787

    Article  CAS  Google Scholar 

  29. Sehouli J, Stengel D, Oskay-oezcelik G et al (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26:3176–3182. https://doi.org/10.1200/JCO.2007.15.1258

    Article  CAS  PubMed  Google Scholar 

  30. Takasaki K, Miyamoto M, Takano M et al (2018) Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer Chemother Pharmacol 81:809–814. https://doi.org/10.1007/s00280-018-3552-5

    Article  CAS  PubMed  Google Scholar 

  31. Nagao S, Kogiku A, Suzuki K et al (2020) A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Ovarian Res 13:1–6. https://doi.org/10.1186/s13048-020-0617-y

    Article  CAS  Google Scholar 

  32. Takase N, Matsumoto K, Onoe T et al (2015) 4-Step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol 20:566–573. https://doi.org/10.1007/s10147-014-0731-1

    Article  CAS  PubMed  Google Scholar 

  33. Inayama Y, Hamanishi J, Matsumura N et al (2018) Antitumor effect of nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer. Oncologist 23:1382–1384. https://doi.org/10.1634/theoncologist.2018-0167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hamanishi J, Mandai M, Ikeda T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015–4022. https://doi.org/10.1200/JCO.2015.62.3397

    Article  CAS  PubMed  Google Scholar 

  35. Matulonis UA, Santin AD, Lisyanskaya AS et al (2019) Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 30:1080–1087. https://doi.org/10.1093/annonc/mdz135

    Article  CAS  PubMed  Google Scholar 

  36. Liu JF, Herold C, Gray KP et al (2019) Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol 5:1731–1738. https://doi.org/10.1001/jamaoncol.2019.3343

    Article  PubMed  PubMed Central  Google Scholar 

  37. Domchek SM, Aghajanian C, Shapira-frommer R et al (2016) Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 140:199–203. https://doi.org/10.1016/j.ygyno.2015.12.020

    Article  CAS  PubMed  Google Scholar 

  38. Pfisterer J, Shannon CM, Baumann K et al (2020) Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 21:699–709. https://doi.org/10.1016/S1470-2045(20)30142-X

    Article  CAS  PubMed  Google Scholar 

  39. Ito K, Nakagawa M, Hori K et al (2020) 834P A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial). Ann Oncol 31:S627. https://doi.org/10.1016/j.annonc.2020.08.973

    Article  Google Scholar 

  40. Poveda AM, Selle F, Hilpert F et al (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III aurelia trial. J Clin Oncol 33:3836–3838. https://doi.org/10.1200/JCO.2015.63.1408

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Editage (www.editage.com) for English language editing.

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan

    Hiroki Nasu, Shin Nishio, Jongmyung Park, Teruyuki Yoshimitsu, Ken Matsukuma, Kazuto Tasaki, Takahiro Katsuda, Atsumu Terada, Naotake Tsuda & Kimio Ushijima

Authors
  1. Hiroki Nasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jongmyung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruyuki Yoshimitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken Matsukuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuto Tasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takahiro Katsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsumu Terada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naotake Tsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kimio Ushijima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Nasu.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nasu, H., Nishio, S., Park, J. et al. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer. Int J Clin Oncol 27, 790–801 (2022). https://doi.org/10.1007/s10147-021-02103-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-02103-7

Keywords

Search

Navigation